Friday, August 28, 2015

Bristol-Myers Squibb completes tender offer of Amylin

Bristol-Myers Squibb said Wednesday it had completed its tender offer for Amylin Pharmaceuticals, Inc., which is expected to amount to a $7 billion acquisition.

Bristol-Myers Squibb completes tender offer of Amylin

0 comments

Bristol-Myers Squibb said Wednesday it had completed its tender offer for Amylin Pharmaceuticals, Inc., which is expected to amount to a $7 billion acquisition.

Amylin becomes a subsidiary of BMS, which is based in Princeton.

After the deal closes, the next step in the two pronged deal is for AstraZeneca to spend $3.4 billion to join the Amylin subsidiary in developing and selling Amylin's diabetes drugs.

AstraZeneca, which is trying overcome patent expirations and other challenges, has operations in Wilmington and Newark, Del.

The stock purchase price for Amylin was $31 per share.

0 comments
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy:

Philly.com comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by Philly.com staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
 
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at dsell@phillynews.com or 215-854-4506.

David Sell
Also on Philly.com:
letter icon Newsletter